Abstract Background Prostate cancer (PCa) is characterized as the most frequent type of
cancer in males. Recent research has suggested patients who have diabetes mellitus taking …

Objectives Metformin has numerous antineoplastic effects including an AMP-activated
protein kinase–dependent mechanism, AMP-activated protein kinase–independent …

Metformin, an oral biguanide used for first-line treatment of type 2 diabetes mellitus, has
attracted attention for its anti-proliferative and anti-cancer effects in several solid tumors …

Abstract Purpose of Review Since epidemiological studies first demonstrated a potential
positive effect of metformin in reducing cancer incidence and mortality, there has been an …

Background Metformin has been implicated to reduce the risk of prostate cancer (PCa)
beyond its glucose-lowering effect. However, the influence of metformin on prognosis of PCa …

Background: Conflicting evidence exists regarding the beneficial effects of metformin in
prostate cancer. To determine the association between metformin and clinical outcomes in …

Background Laboratory studies have shown the anti-tumor effect of metformin on prostate
cancer. However, recent epidemiological studies have yielded inconclusive results. Methods …

The relationship between metformin and prostate cancer (PCa) remains controversial. To
clarify this association, the PubMed, Embase and Cochrane library databases were …

Prostate cancer (PCa) has become the most frequent type of cancer in men. Recent data
suggest that diabetic patients taking metformin have a lower incidence of certain cancer …

Objective Previous studies suggested that metformin is associated with decreased risk of
cancer; however, results specifically addressing the potential association with prostate …